Simple Summary There is still a lack of reliable molecular predictors to achieve major
molecular response (MMR, BCR:: ABL1≤ 0.1% IS) within the first year of treatment with …

Despite the unprecedented success of tyrosine kinase inhibitors (TKIs), the clinical
management of 20–30% of patients with chronic myeloid leukemia (CML) experiencing …

Separase, a cysteine endopeptidase, is a key player in mitotic sister chromatid separation,
replication fork dynamics, and DNA repair. Aberrant expression and/or altered separase …

Several studies have now shown that chronic myeloid leukaemia (CML) patients in deep
molecular remission may discontinue tyrosine kinase inhibitor (TKI) treatment with a …

Background Genomic instability and clonal evolution are hallmarks of progressing chronic
myeloid leukemia (CML). Recently, we have shown that clonal evolution and blast crisis …

Differential gene expression analysis by suppression subtractive hybridization with
correlation to the metabolic pathways involved in chronic myeloid leukemia (CML) may …

BACKGROUND: In chronic phase chronic myeloid leukemia (CP-CML) patients treated with
frontline imatinib, failure to achieve early molecular response (EMR failure: BCR-ABL1> …

Backgrounds: We aimed to evaluate the predictive efficacy of baseline 18F-FDG PET/CT-
based radiomics analysis for EGFR mutation status, mutation site, and the survival benefit of …

Liquid biopsy is a tool to unveil resistance mechanisms in NSCLC. We studied changes in
gene expression in CTC-enriched fractions of EGFR-mutant NSCLC patients under …

Background: Tumor-infiltrating immune cells (TIICs) are associated with chemotherapy
response. This study aimed to explore the prognostic value of a TIIC-related tumor …